Yuting Ma
Papers
1
Total Citations
129
H-Index
1
About
Dr. Yuting Ma is a leading immunologist whose research focuses on the mechanisms of immunogenic cell death (ICD) and the development of novel cancer immunotherapies. Her most cited work, "The oncolytic peptide LTX-315 triggers immunogenic cell death" (2016, 129 citations), represents a major contribution to the field. In this seminal study, Dr. Ma demonstrated that the cationic amphilytic peptide LTX-315 preferentially permeabilizes mitochondrial membranes, inducing a partially BAX/BAK1-regulated, caspase-independent necrosis. Crucially, she showed that intratumoral injection of LTX-315 not only kills cancer cells but also stimulates a robust T lymphocyte-mediated anticancer immune response, effectively turning the tumor into its own vaccine. This discovery has profound implications for designing therapies that combine direct tumor destruction with immune activation. Dr. Ma’s work bridges fundamental cell death biology and translational oncology, establishing her as a key figure in understanding how to harness ICD for clinical benefit. Her research continues to shape the development of next-generation oncolytic agents that can overcome resistance and potentiate checkpoint blockade therapies.
Research Focus
Key Achievements
Top Papers
- 1The oncolytic peptide LTX-315 triggers immunogenic cell death129 citations · 2016